AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted its application for the self-administration of the FluMist Quadrivalent nasal flu vaccine, potentially making it the first flu vaccine that patients or caregivers can administer without a healthcare practitioner's assistance. Initially approved by the FDA in 2003, AstraZeneca anticipates a decision from the FDA in the first quarter of 2024, with the self-administered vaccine expected to be available in the United States for the 2024-2025 flu season if approved. The application is supported by a usability study showing that individuals over 18 can effectively self-administer or administer the vaccine to eligible patients aged 2-49 when provided with usage instructions alone.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!